Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
ZNTL Price/Volume Stats
| Current price | $1.47 | 52-week high | $11.92 |
| Prev. close | $1.50 | 52-week low | $1.01 |
| Day low | $1.46 | Volume | 1,045,300 |
| Day high | $1.60 | Avg. volume | 1,364,077 |
| 50-day MA | $1.33 | Dividend yield | N/A |
| 200-day MA | $2.51 | Market Cap | 105.77M |
ZNTL Stock Price Chart Interactive Chart >
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
ZNTL Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZNTL Price Returns
| 1-mo | 19.51% |
| 3-mo | -19.23% |
| 6-mo | -58.00% |
| 1-year | -86.73% |
| 3-year | -94.58% |
| 5-year | -96.78% |
| YTD | -51.49% |
| 2024 | -80.00% |
| 2023 | -24.78% |
| 2022 | -76.04% |
| 2021 | 61.84% |
| 2020 | N/A |